Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy

Menopause

Volumn 9, Issue 1, 2002, Pages 16-22

  Johnson, Julia V ^a   Davidson, Michael ^a   Archer, David ^a   Bachmann, Gloria ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Bleeding profiles; CCHRT; Postmenopausal; Uterine bleeding

Indexed keywords

CHOLESTEROL; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL PLUS NORETHISTERONE ACETATE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; ENDOMETRIUM BIOPSY; FEMALE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; MENSTRUAL CYCLE; MULTICENTER STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SCREENING; TRIACYLGLYCEROL BLOOD LEVEL; UTERUS BLEEDING;

EID: 0036156413     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042192-200201000-00004     Document Type: Article

References (26)

1. Estrace® vs Premarin® for treatment of menopausal symptoms: Dosage comparison study
2. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen therapy
3. Low-dosage micronized 17β-estradiol prevents bone loss in postmenopausal women
4. Endometrial disease after treatment with oestrogens and progestagens in the climacteric
5. Progestagen supplementation of exogenous estrogens and risk of endometrial cancer
6. Evaluation of a continuous oestrogen-pregestogen regimen for climacteric complaints
7. Women's attitudes and knowledge about the climacteric period and its treatment. A Swedish population-based study
8. Quality of life and patient preference for sequential versus continuous combined HRT: The UK Kliofem multicentre study experience
9. Estrogen replacement therapy. A survey of women's knowledge and attitudes
10. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic centre
11. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate
12. Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy
13. Initial 17β-estradiol dose for treating vasomotor symptoms
14. 17β-estradiol and norethisterone acetate in low doses as continuous combined hormone replacement therapy
15. Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate
16. Assessment of the potency of orally administered progestins in women
17. Norethindrone acetate and estradiol-induced endometrial hyperplasia
18. Optimizing continuous combined hormone replacement therapy for postmenopausal women: A comparison of six different treatment regimens
19. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause
20. Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations
21. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause
22. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone
23. Optimizing continuous combined hormone replacement therapy in postmenopausal women: A comparison of six different treatment regimens
24. Risk of endometrial cancer following estrogen replacement with and without progestins
25. Continuous combined hormone replacement therapy and risks of endometrial cancer
26. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women